Retractable Technologies Inc

Retractable Technologies Inc (RVP) Stock Analysis

$0.569

+0.003 (+0.60%)At close

Loading chart…
High
0.582
Open
0.578
VWAP
0.57
Volume
51.72K
Mkt Cap
32.63M
Low
0.562
Amount
29.53K
EV/EBITDA, TTM
0.00

Retractable Technologies, Inc. is engaged in the manufacturing and marketing of safety medical products (predominately syringes) for the healthcare industry. The Company is focused on the production of injection devices (syringes and needles). Such products are marketed under the VanishPoint, Patient Safe, and EasyPoint brands. The VanishPoint syringe, blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient, effectively reducing exposure to the contaminated needle. Patient Safe syringes are designed to reduce the risk of bloodstream infections resulting from catheter hub contamination. The EasyPoint is a retractable needle that can be used with luer lock syringes, luer slip syringes, and prefilled syringes to give injections. The EasyPoint needle can also be used to aspirate fluids and for blood collection. Its products are distributed by various specialty and general line distributors.

AI analysis of Retractable Technologies Inc (RVP)

Sell

Retractable Technologies Inc is not a good buy right now due to its declining financial performance and negative market sentiment. The current price is $0.5694, and the company has reported a significant net loss of $4.2 million in Q1 2026, alongside a 13.3% year-over-year decline in sales. Additionally, the RSI is at 27.179, indicating that the stock is oversold, but this does not outweigh the financial risks. The main risk is the ongoing operational losses, which have widened to $6.2 million, suggesting challenges in achieving profitability.

Valuation Metrics

The current forward P/E ratio for Retractable Technologies Inc (RVP) is 0.00, compared to its 5-year average forward P/E of 0.00.

Forward P/E

Strongly Undervalued
5Y Average P/E
0.00
Current P/E
0.00
Overvalued
0.00
Undervalued
0.00

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued
0.00
Undervalued
0.00

Forward P/S

Strongly Undervalued
5Y Average P/S
0.00
Current P/S
0.00
Overvalued
0.00
Undervalued
0.00

Alphio AI Price Scenarios for RVP

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%RVP

$0.71

Scenario price

B

Base

Base · 50%RVP

$0.66

Scenario price

B

Bear

Bear · 25%RVP

$0.57

Scenario price

RVP FAQ — answered by Alphio AI

Retractable Technologies, Inc. is engaged in the manufacturing and marketing of safety medical products (predominately syringes) for the healthcare industry. The Company is focused on the production of injection devices (syringes and needles). Such products are marketed under the VanishPoint, Patient Safe, and EasyPoint brands. The VanishPoint syringe, blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient, effectively reducing exposure to the contaminated needle. Patient Safe syringes are designed to reduce the risk of bloodstream infections resulting from catheter hub contamination. The EasyPoint is a retractable needle that can be used with luer lock syringes, luer slip syringes, and prefilled syringes to give injections. The EasyPoint needle can also be used to aspirate fluids and for blood collection. Its products are distributed by various specialty and general line distributors. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Retractable Technologies Inc is not a good buy right now due to its declining financial performance and negative market sentiment. The current price is $0.5694, and the company has reported a significant net loss of $4.2 million in Q1 2026, alongside a 13.3% year-over-year decline in sales. Additionally, the RSI is at 27.179, indicating that the stock is oversold, but this does not outweigh the financial risks. The main risk is the ongoing operational losses, which have widened to $6.2 million, suggesting challenges in achieving profitability.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

Related articles

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading